Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find PharmaFlow Article for Naproxen Sodium

    Client Email Product

    Naproxen Sodium

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    DOSSIERs // Finished Dosage Formulations

    DRUG PRODUCT COMPOSITION

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Related ProductsRelated Products
    API SUPPLIERS
    API Suppliers

    API Suppliers

    31
    US DMFs Filed

    US DMFs Filed

    23
    CEP/COS Certifications

    CEP/COS Certifications

    7
    JDMFs Filed

    JDMFs Filed

    0

    EU WC

    EU WC

    6
    Listed Suppliers

    Listed Suppliers

    9
    API REF. PRICE (USD / KG)
    37

    API Market Place

    35
    INTERMEDIATES

    0

    DOSSIERS // FDF
    USA (Orange Book)

    USA (Orange Book)

    85
    Europe

    Europe

    13
    Canada

    Canada

    19
    Australia

    Australia

    0

    South Africa

    South Africa

    4
    Uploaded Dossiers

    Uploaded Dossiers

    24
    GLOBAL SALES (USD Million)

    U.S. Medicaid

    167.00

    Annual Reports

    0

    FDF Market Place

    2
    EXCIPIENTS
    352
    PATENTS & EXCLUSIVITIES

    USFDA Orange Book Patents

    12

    USFDA Exclusivities

    0

    DIGITAL CONTENT

    Blog #PharmaFlow

    1

    News

    44
    REF STANDARD

    EDQM

    3

    USP

    1

    JP

    0

    Other Listed Suppliers

    1
    SERVICES
    1
    left grey arrow
    right gray arrow
    • TABLET;ORAL - EQ 250MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
    • TABLET;ORAL - EQ 500MG BASE
    • TABLET;ORAL - 220MG
    • TABLET, EXTENDED RELEASE;ORAL - EQ 375MG BASE
    • TABLET, EXTENDED RELEASE;ORAL - EQ 500MG BASE
    • TABLET, EXTENDED RELEASE;ORAL - EQ 750MG BASE
    • CAPSULE;ORAL - EQ 200MG BASE
    • TABLET;ORAL - 500MG;EQ 85MG BASE
    • TABLET;ORAL - 60MG;EQ 10MG BASE
    BlogBlog
    Full View ScreenFull Screen View
    Divi’s Labs on FDA’s Import Alert List; but did it refuse an inspection?

    Divi’s Labs on FDA’s Import Alert List; but did it refuse an inspection?

    Divi's Laboratories — an Indian active pharmaceutical ingredient (API) manufacturer and until recently the darling of the Indian bourses — received another setback this week.  The US Food and Drug Administration (FDA) placed its Unit II, located in Visakhapatnam, on its import alert list for “refusing FDA foreign establishment inspection” as also for “not meeting drug GMPs” (good manufacturing practices). According to the FDA website “the refusal to permit inspection of a foreign facility or provide reasonable access to FDA’s inspectional personnel, combined with other evidence, provides an appearance that the firm’s products are manufactured, processed, or packed under insanitary conditions.” The firm is considered to have refused the FDA inspection. This news comes as a surprise, as it adds an additional dimension to the problems that the FDA encountered at Divi’s facilities.  PharmaCompass had previously shared news that Health Canada had placed the company on its inspection tracker after data integrity and general GMP observations were reported by its “regulatory partner(s)”.  According to media reports, the firm was inspected by the US FDA from November 29 to December 6, 2016, and the regulators had issued an 18-page long Form 483 with five observations. Second Divi’s group firm to refuse inspection   The news comes a few months after its affiliate – Divi’s Pharmaceutical Private Ltd was placed on FDA’s Import Alert List for refusing an inspection by the US FDA. The two facilities of Divi’s Pharmaceutical  that were placed on the FDA’s Red List were Divi Towers in Hyderabad, and a facility in Medak district, Telangana. Divi Towers is also the corporate headquarters of Divi’s Laboratories. Divi’s Laboratories’ Unit-II is a major producer of APIs and a key supplier to leading companies around the world. The FDA has excluded some intermediates and the following APIs from the import alerts – Levetiracetam, Gabapentin, Lamotrigine, Capecitabine, Naproxen sodium , Raltegravir potassium and Atovaquone.  The exemptions did not help as far as the stock market was concerned. Divi’s stock price, which has already been under significant pressure after news of the inspection initially broke out in December, tanked another 20 percent on Tuesday. Our view   While the details are yet to emerge on the exact nature of problems which the US FDA inspectors uncovered and encountered at Divi’s Laboratories Unit II, it is clear that Divi’s has a long road ahead insofar as regulatory compliance is concerned.

    Impressions: 3526

    subscribeSubscribe
    ExcelExcel Download

    https://www.pharmacompass.com/radio-compass-blog/divi-s-labs-on-fda-s-import-alert-list-but-did-it-refuse-an-inspection

    #Phispers by PHARMACOMPASS
    23 Mar 2017
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-2024-05-06

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search